A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension
Phase of Trial: Phase III
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Azilsartan medoxomil (Primary) ; Valsartan
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 05 Jan 2018 Status changed from recruiting to completed.
- 12 Sep 2017 Planned End Date changed from 25 Aug 2017 to 9 Oct 2017.
- 12 Sep 2017 Planned primary completion date changed from 25 Aug 2017 to 9 Oct 2017.